China approves CSPC, CanSino mRNA vaccines for clinical trial, boosting country’s arsenal against raging Omicron outbreak

The approvals add CanSino and CSPC to the race among Chinese companies to use mRNA to fight the coronavirus, offering viable alternatives to the vaccines already in production by Pfizer and Moderna.

Read the original article at South China Morning Post